25 XP   0   0   10

Shenzhen Hepalink Pharmaceutical 
Buy, Hold or Sell?

Let's analyse Hepalink together

PenkeI guess you are interested in Shenzhen Hepalink Pharmaceutical . Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Shenzhen Hepalink Pharmaceutical . At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Shenzhen Hepalink Pharmaceutical 

I send you an email if I find something interesting about Shenzhen Hepalink Pharmaceutical .

Quick analysis of Hepalink (30 sec.)










What can you expect buying and holding a share of Hepalink? (30 sec.)

How much money do you get?

How much money do you get?
HK$0.04
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
HK$8.82
Expected worth in 1 year
HK$8.59
How sure are you?
66.7%

+ What do you gain per year?

Total Gains per Share
HK$0.08
Return On Investment
2.5%

For what price can you sell your share?

Current Price per Share
HK$3.07
Expected price per share
HK$2.66 - HK$3.68
How sure are you?
50%

1. Valuation of Hepalink (5 min.)




Live pricePrice per Share (EOD)

HK$3.07

Intrinsic Value Per Share

HK$9.54 - HK$11.63

Total Value Per Share

HK$18.36 - HK$20.45

2. Growth of Hepalink (5 min.)




Is Hepalink growing?

Current yearPrevious yearGrowGrow %
How rich?$1.6b$1.6b$23.2m1.4%

How much money is Hepalink making?

Current yearPrevious yearGrowGrow %
Making money-$24.7m$29.9m-$54.6m-221.1%
Net Profit Margin-14.0%10.6%--

How much money comes from the company's main activities?

3. Financial Health of Hepalink (5 min.)




What can you expect buying and holding a share of Hepalink? (5 min.)

Welcome investor! Hepalink's management wants to use your money to grow the business. In return you get a share of Hepalink.

What can you expect buying and holding a share of Hepalink?

First you should know what it really means to hold a share of Hepalink. And how you can make/lose money.

Speculation

The Price per Share of Hepalink is HK$3.07. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Hepalink.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Hepalink, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is HK$8.82. Based on the TTM, the Book Value Change Per Share is HK$-0.06 per quarter. Based on the YOY, the Book Value Change Per Share is HK$0.14 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is HK$0.08 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Hepalink.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 HK$% of Price per ShareHK$% of Price per ShareHK$% of Price per ShareHK$% of Price per ShareHK$% of Price per Share
Usd Eps-0.09-2.8%-0.02-0.6%0.020.6%0.010.4%0.010.4%
Usd Book Value Change Per Share-0.05-1.6%-0.01-0.2%0.020.6%0.062.0%0.062.0%
Usd Dividend Per Share0.020.5%0.010.3%0.010.2%0.010.5%0.010.5%
Usd Total Gains Per Share-0.03-1.0%0.000.1%0.020.8%0.082.5%0.082.5%
Usd Price Per Share0.46-0.56-0.75-0.75-0.75-
Price to Earnings Ratio-1.31-30.51-14.39-15.92-15.92-
Price-to-Total Gains Ratio-14.51--46.20-1.68--41.61--41.61-
Price to Book Ratio0.41-0.48-0.66-0.67-0.67-
Price-to-Total Gains Ratio-14.51--46.20-1.68--41.61--41.61-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.392039
Number of shares2550
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.01
Usd Book Value Change Per Share-0.010.06
Usd Total Gains Per Share0.000.08
Gains per Quarter (2550 shares)6.19196.89
Gains per Year (2550 shares)24.77787.57
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1102-7715149638778
2204-1554029812771566
3306-2326544719152354
4408-3099059725543142
5510-38611574631923930
6612-46414089538314718
7714-541165104444695506
8816-618190119351076294
9919-696215134257467082
101021-773240149163847870

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%10.02.00.083.3%16.02.00.088.9%16.02.00.088.9%16.02.00.088.9%
Book Value Change Per Share2.02.00.050.0%7.05.00.058.3%12.06.00.066.7%12.06.00.066.7%12.06.00.066.7%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%18.00.00.0100.0%18.00.00.0100.0%18.00.00.0100.0%
Total Gains per Share2.02.00.050.0%7.05.00.058.3%12.06.00.066.7%12.06.00.066.7%12.06.00.066.7%

Fundamentals of Hepalink

About Shenzhen Hepalink Pharmaceutical 

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, production, and sell of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.

Fundamental data was last updated by Penke on 2024-04-18 23:32:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Shenzhen Hepalink Pharmaceutical .

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Hepalink earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Hepalink to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -67.0% means that $-0.67 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Shenzhen Hepalink Pharmaceutical :

  • The MRQ is -67.0%. The company is making a huge loss. -2
  • The TTM is -14.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-67.0%TTM-14.0%-53.0%
TTM-14.0%YOY10.6%-24.5%
TTM-14.0%5Y7.4%-21.3%
5Y7.4%10Y7.4%0.0%
1.1.2. Return on Assets

Shows how efficient Hepalink is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Hepalink to the Drug Manufacturers - Specialty & Generic industry mean.
  • -4.8% Return on Assets means that Hepalink generated $-0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Shenzhen Hepalink Pharmaceutical :

  • The MRQ is -4.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -1.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-4.8%TTM-1.0%-3.9%
TTM-1.0%YOY1.0%-2.0%
TTM-1.0%5Y0.7%-1.6%
5Y0.7%10Y0.7%0.0%
1.1.3. Return on Equity

Shows how efficient Hepalink is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Hepalink to the Drug Manufacturers - Specialty & Generic industry mean.
  • -7.8% Return on Equity means Hepalink generated $-0.08 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Shenzhen Hepalink Pharmaceutical :

  • The MRQ is -7.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -1.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.8%TTM-1.5%-6.3%
TTM-1.5%YOY1.8%-3.3%
TTM-1.5%5Y1.3%-2.9%
5Y1.3%10Y1.3%0.0%

1.2. Operating Efficiency of Shenzhen Hepalink Pharmaceutical .

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Hepalink is operating .

  • Measures how much profit Hepalink makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Hepalink to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Shenzhen Hepalink Pharmaceutical :

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM7.5%-7.5%
TTM7.5%YOY11.8%-4.3%
TTM7.5%5Y14.7%-7.2%
5Y14.7%10Y14.7%0.0%
1.2.2. Operating Ratio

Measures how efficient Hepalink is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.56 means that the operating costs are $1.56 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Shenzhen Hepalink Pharmaceutical :

  • The MRQ is 1.559. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.449. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.559TTM1.449+0.111
TTM1.449YOY1.418+0.030
TTM1.4495Y1.427+0.022
5Y1.42710Y1.4270.000

1.3. Liquidity of Shenzhen Hepalink Pharmaceutical .

1.3. Liquidity
1.3.1. Current Ratio

Measures if Hepalink is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.13 means the company has $2.13 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Shenzhen Hepalink Pharmaceutical :

  • The MRQ is 2.127. The company is able to pay all its short-term debts. +1
  • The TTM is 2.297. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.127TTM2.297-0.171
TTM2.297YOY2.046+0.251
TTM2.2975Y2.104+0.193
5Y2.10410Y2.1040.000
1.3.2. Quick Ratio

Measures if Hepalink is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Hepalink to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.34 means the company can pay off $0.34 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Shenzhen Hepalink Pharmaceutical :

  • The MRQ is 0.336. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.492. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.336TTM0.492-0.156
TTM0.492YOY0.847-0.356
TTM0.4925Y0.800-0.308
5Y0.80010Y0.8000.000

1.4. Solvency of Shenzhen Hepalink Pharmaceutical .

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Hepalink assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Hepalink to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.38 means that Hepalink assets are financed with 37.6% credit (debt) and the remaining percentage (100% - 37.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Shenzhen Hepalink Pharmaceutical :

  • The MRQ is 0.376. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.388. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.376TTM0.388-0.013
TTM0.388YOY0.419-0.030
TTM0.3885Y0.424-0.036
5Y0.42410Y0.4240.000
1.4.2. Debt to Equity Ratio

Measures if Hepalink is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Hepalink to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 60.6% means that company has $0.61 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Shenzhen Hepalink Pharmaceutical :

  • The MRQ is 0.606. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.639. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.606TTM0.639-0.033
TTM0.639YOY0.726-0.087
TTM0.6395Y0.760-0.122
5Y0.76010Y0.7600.000

2. Market Valuation of Shenzhen Hepalink Pharmaceutical 

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Hepalink generates.

  • Above 15 is considered overpriced but always compare Hepalink to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -1.31 means the investor is paying $-1.31 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Shenzhen Hepalink Pharmaceutical :

  • The EOD is -1.126. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.313. Based on the earnings, the company is expensive. -2
  • The TTM is 30.509. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD-1.126MRQ-1.313+0.187
MRQ-1.313TTM30.509-31.822
TTM30.509YOY14.389+16.120
TTM30.5095Y15.919+14.590
5Y15.91910Y15.9190.000
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Shenzhen Hepalink Pharmaceutical :

  • The EOD is 2.257. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 2.631. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 0.084. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD2.257MRQ2.631-0.375
MRQ2.631TTM0.084+2.547
TTM0.084YOY-20.797+20.881
TTM0.0845Y-0.560+0.644
5Y-0.56010Y-0.5600.000
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Hepalink is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Shenzhen Hepalink Pharmaceutical :

  • The EOD is 0.348. Based on the equity, the company is cheap. +2
  • The MRQ is 0.406. Based on the equity, the company is cheap. +2
  • The TTM is 0.479. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.348MRQ0.406-0.058
MRQ0.406TTM0.479-0.073
TTM0.479YOY0.660-0.182
TTM0.4795Y0.672-0.194
5Y0.67210Y0.6720.000
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Shenzhen Hepalink Pharmaceutical  compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.376-0.059-84%0.139-371%0.490-177%0.490-177%
Book Value Per Share--8.8229.081-3%8.957-1%9.880-11%9.880-11%
Current Ratio--2.1272.297-7%2.046+4%2.104+1%2.104+1%
Debt To Asset Ratio--0.3760.388-3%0.419-10%0.424-11%0.424-11%
Debt To Equity Ratio--0.6060.639-5%0.726-17%0.760-20%0.760-20%
Dividend Per Share--0.1290.078+65%0.046+179%0.115+13%0.115+13%
Eps---0.682-0.144-79%0.132-616%0.106-743%0.106-743%
Free Cash Flow Per Share--0.340-0.009+103%-0.180+153%-0.067+120%-0.067+120%
Free Cash Flow To Equity Per Share--0.340-0.132+139%-0.024+107%0.036+833%0.036+833%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--11.628--------
Intrinsic Value_10Y_min--9.541--------
Intrinsic Value_1Y_max---0.089--------
Intrinsic Value_1Y_min---0.088--------
Intrinsic Value_3Y_max--0.689--------
Intrinsic Value_3Y_min--0.639--------
Intrinsic Value_5Y_max--2.619--------
Intrinsic Value_5Y_min--2.349--------
Market Cap675688580.000-677%5252920410.3206386406723.610-18%8664384079.160-39%8617919702.658-39%8617919702.658-39%
Net Profit Margin---0.670-0.140-79%0.106-735%0.074-1011%0.074-1011%
Operating Margin---0.075-100%0.118-100%0.147-100%0.147-100%
Operating Ratio--1.5591.449+8%1.418+10%1.427+9%1.427+9%
Pb Ratio0.348-17%0.4060.479-15%0.660-39%0.672-40%0.672-40%
Pe Ratio-1.126+14%-1.31330.509-104%14.389-109%15.919-108%15.919-108%
Price Per Share3.070-17%3.5804.353-18%5.905-39%5.873-39%5.873-39%
Price To Free Cash Flow Ratio2.257-17%2.6310.084+3030%-20.797+890%-0.560+121%-0.560+121%
Price To Total Gains Ratio-12.439+14%-14.505-46.198+218%1.676-966%-41.612+187%-41.612+187%
Quick Ratio--0.3360.492-32%0.847-60%0.800-58%0.800-58%
Return On Assets---0.048-0.010-80%0.010-564%0.007-806%0.007-806%
Return On Equity---0.078-0.015-80%0.018-531%0.013-684%0.013-684%
Total Gains Per Share---0.2470.019-1398%0.185-234%0.605-141%0.605-141%
Usd Book Value--1653082918.0261701461238.593-3%1678224001.402-1%1517940285.385+9%1517940285.385+9%
Usd Book Value Change Per Share---0.048-0.008-84%0.018-371%0.063-177%0.063-177%
Usd Book Value Per Share--1.1271.160-3%1.144-1%1.262-11%1.262-11%
Usd Dividend Per Share--0.0160.010+65%0.006+179%0.015+13%0.015+13%
Usd Eps---0.087-0.018-79%0.017-616%0.014-743%0.014-743%
Usd Free Cash Flow--63728009.622-1608560.511+103%-33749862.265+153%-10735479.529+117%-10735479.529+117%
Usd Free Cash Flow Per Share--0.043-0.001+103%-0.023+153%-0.009+120%-0.009+120%
Usd Free Cash Flow To Equity Per Share--0.043-0.017+139%-0.003+107%0.005+833%0.005+833%
Usd Market Cap86285431.666-677%670797936.398815544138.605-18%1106441846.909-39%1100508346.029-39%1100508346.029-39%
Usd Price Per Share0.392-17%0.4570.556-18%0.754-39%0.750-39%0.750-39%
Usd Profit---127745605.233-24707173.233-81%29928946.901-527%16811570.381-860%16811570.381-860%
Usd Revenue--190611360.123232343368.881-18%303010198.917-37%239780447.710-21%239780447.710-21%
Usd Total Gains Per Share---0.0320.002-1398%0.024-234%0.077-141%0.077-141%
 EOD+4 -4MRQTTM+13 -22YOY+13 -225Y+15 -2010Y+15 -20

3.2. Fundamental Score

Let's check the fundamental score of Shenzhen Hepalink Pharmaceutical  based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.126
Price to Book Ratio (EOD)Between0-10.348
Net Profit Margin (MRQ)Greater than0-0.670
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.336
Current Ratio (MRQ)Greater than12.127
Debt to Asset Ratio (MRQ)Less than10.376
Debt to Equity Ratio (MRQ)Less than10.606
Return on Equity (MRQ)Greater than0.15-0.078
Return on Assets (MRQ)Greater than0.05-0.048
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Shenzhen Hepalink Pharmaceutical  based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5066.464
Ma 20Greater thanMa 502.825
Ma 50Greater thanMa 1002.810
Ma 100Greater thanMa 2003.031
OpenGreater thanClose3.010
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Income before Tax  216,835-133,08883,74797,366181,113-166,59314,519-1,212,567-1,198,047
Net Income  233,169-161,31971,85061,342133,192-111,79021,402-1,021,759-1,000,357
Interest Income  180,741-168,59012,151364,124376,276-313,05263,224-69,151-5,927
Net Income from Continuing Operations  69,7811,43171,211-10,29160,920-39,84421,076-1,040,456-1,019,379



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in CNY. All numbers in thousands.

Summary
Total Assets19,203,415
Total Liabilities7,215,037
Total Stockholder Equity11,913,149
 As reported
Total Liabilities 7,215,037
Total Stockholder Equity+ 11,913,149
Total Assets = 19,203,415

Assets

Total Assets19,203,415
Total Current Assets10,603,905
Long-term Assets8,599,511
Total Current Assets
Cash And Cash Equivalents 1,851,642
Short-term Investments 414,184
Net Receivables 1,260,402
Inventory 6,654,111
Other Current Assets 177,923
Total Current Assets  (as reported)10,603,905
Total Current Assets  (calculated)10,358,262
+/- 245,643
Long-term Assets
Property Plant Equipment 2,634,225
Goodwill 2,322,375
Intangible Assets 493,216
Long-term Assets Other 121,836
Long-term Assets  (as reported)8,599,511
Long-term Assets  (calculated)5,571,652
+/- 3,027,858

Liabilities & Shareholders' Equity

Total Current Liabilities4,986,180
Long-term Liabilities2,228,857
Total Stockholder Equity11,913,149
Total Current Liabilities
Short Long Term Debt 1,880,741
Accounts payable 302,223
Total Current Liabilities  (as reported)4,986,180
Total Current Liabilities  (calculated)2,182,964
+/- 2,803,217
Long-term Liabilities
Long term Debt 1,810,021
Capital Lease Obligations Min Short Term Debt90,417
Long-term Liabilities Other 9,743
Long-term Liabilities  (as reported)2,228,857
Long-term Liabilities  (calculated)1,910,181
+/- 318,676
Total Stockholder Equity
Retained Earnings 3,385,946
Total Stockholder Equity (as reported)11,913,149
Total Stockholder Equity (calculated)3,385,946
+/- 8,527,203
Other
Capital Stock1,467,296
Common Stock Shares Outstanding 1,467,296
Net Debt 1,839,120
Net Invested Capital 15,603,911
Net Working Capital 5,617,724
Property Plant and Equipment Gross 2,634,225



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-30
> Total Assets 
14,807,436
15,242,205
15,846,107
16,585,101
18,512,740
19,025,895
19,391,184
18,977,259
19,265,416
19,350,961
20,130,477
21,361,912
21,469,099
20,814,204
20,623,023
20,787,431
20,120,561
19,203,415
19,203,41520,120,56120,787,43120,623,02320,814,20421,469,09921,361,91220,130,47719,350,96119,265,41618,977,25919,391,18419,025,89518,512,74016,585,10115,846,10715,242,20514,807,436
   > Total Current Assets 
5,533,974
5,995,531
6,385,282
6,902,979
8,850,168
9,128,708
10,245,387
10,175,662
10,704,691
10,769,653
11,843,113
12,938,941
12,883,684
12,472,311
12,397,138
12,541,308
11,859,084
10,603,905
10,603,90511,859,08412,541,30812,397,13812,472,31112,883,68412,938,94111,843,11310,769,65310,704,69110,175,66210,245,3879,128,7088,850,1686,902,9796,385,2825,995,5315,533,974
       Cash And Cash Equivalents 
1,343,025
1,277,767
1,092,275
1,351,904
2,928,107
2,712,424
3,245,511
3,387,167
3,754,393
1,479,633
3,471,470
3,512,245
2,947,232
2,138,779
2,592,593
2,271,929
1,791,293
1,851,642
1,851,6421,791,2932,271,9292,592,5932,138,7792,947,2323,512,2453,471,4701,479,6333,754,3933,387,1673,245,5112,712,4242,928,1071,351,9041,092,2751,277,7671,343,025
       Short-term Investments 
350,809
112,644
26,868
15,373
613,097
828,205
1,524,040
645,737
397,687
2,420,909
988,609
1,342,067
1,250,782
2,061,327
490,239
1,014,370
474,182
414,184
414,184474,1821,014,370490,2392,061,3271,250,7821,342,067988,6092,420,909397,687645,7371,524,040828,205613,09715,37326,868112,644350,809
       Net Receivables 
1,108,200
1,765,690
1,997,692
1,988,334
1,551,112
1,878,289
1,484,906
2,032,115
1,903,879
1,787,258
1,902,587
1,976,509
1,787,242
1,558,972
1,431,607
1,424,485
1,369,094
1,260,402
1,260,4021,369,0941,424,4851,431,6071,558,9721,787,2421,976,5091,902,5871,787,2581,903,8792,032,1151,484,9061,878,2891,551,1121,988,3341,997,6921,765,6901,108,200
       Inventory 
2,066,961
2,374,357
2,658,176
2,972,515
3,344,387
3,168,249
3,440,340
3,612,396
4,158,962
4,707,549
5,064,439
5,750,897
6,503,410
6,843,906
7,524,472
8,166,687
7,805,326
6,654,111
6,654,1117,805,3268,166,6877,524,4726,843,9066,503,4105,750,8975,064,4394,707,5494,158,9623,612,3963,440,3403,168,2493,344,3872,972,5152,658,1762,374,3572,066,961
       Other Current Assets 
146,851
465,073
610,271
503,364
413,465
467,335
474,916
498,247
489,771
349,432
416,008
357,222
395,018
279,967
358,226
424,896
419,188
177,923
177,923419,188424,896358,226279,967395,018357,222416,008349,432489,771498,247474,916467,335413,465503,364610,271465,073146,851
   > Long-term Assets 
9,273,462
9,246,675
9,460,825
9,682,122
9,662,571
9,897,187
9,145,797
8,801,597
8,560,725
8,338,522
8,287,364
8,422,971
8,585,415
8,424,559
8,225,885
8,246,122
8,261,477
8,599,511
8,599,5118,261,4778,246,1228,225,8858,424,5598,585,4158,422,9718,287,3648,338,5228,560,7258,801,5979,145,7979,897,1879,662,5719,682,1229,460,8259,246,6759,273,462
       Property Plant Equipment 
0
2,575,644
2,590,780
2,672,892
2,641,623
2,571,472
2,558,124
2,512,968
2,508,942
2,537,157
2,516,760
2,530,678
2,539,600
2,477,289
2,457,607
2,547,305
2,622,530
2,634,225
2,634,2252,622,5302,547,3052,457,6072,477,2892,539,6002,530,6782,516,7602,537,1572,508,9422,512,9682,558,1242,571,4722,641,6232,672,8922,590,7802,575,6440
       Goodwill 
2,387,550
2,354,908
2,391,668
2,389,778
2,298,839
2,202,566
2,218,228
2,180,691
2,189,232
2,152,201
2,142,918
2,265,521
2,396,631
2,350,992
2,319,632
2,439,163
2,423,636
2,322,375
2,322,3752,423,6362,439,1632,319,6322,350,9922,396,6312,265,5212,142,9182,152,2012,189,2322,180,6912,218,2282,202,5662,298,8392,389,7782,391,6682,354,9082,387,550
       Intangible Assets 
691,419
682,988
677,090
667,863
640,211
631,026
618,608
607,964
597,276
472,969
572,701
578,262
588,798
462,908
556,266
453,825
543,758
493,216
493,216543,758453,825556,266462,908588,798578,262572,701472,969597,276607,964618,608631,026640,211667,863677,090682,988691,419
       Long-term Assets Other 
152,278
189,072
268,062
314,276
2,833,470
287,301
209,811
204,667
200,721
204,064
201,579
254,167
301,261
223,455
145,858
109,759
88,275
121,836
121,83688,275109,759145,858223,455301,261254,167201,579204,064200,721204,667209,811287,3012,833,470314,276268,062189,072152,278
> Total Liabilities 
7,847,926
7,771,095
8,062,868
8,710,784
7,141,430
7,336,905
7,552,577
7,234,454
7,443,375
7,793,106
8,376,455
9,215,918
8,997,213
8,503,289
8,151,172
8,389,807
7,621,518
7,215,037
7,215,0377,621,5188,389,8078,151,1728,503,2898,997,2139,215,9188,376,4557,793,1067,443,3757,234,4547,552,5777,336,9057,141,4308,710,7848,062,8687,771,0957,847,926
   > Total Current Liabilities 
5,478,638
4,967,136
4,685,195
4,762,516
3,743,316
3,612,834
3,681,622
3,612,950
3,909,850
4,791,470
5,732,113
7,117,862
6,241,738
5,575,796
5,134,400
5,513,024
4,997,192
4,986,180
4,986,1804,997,1925,513,0245,134,4005,575,7966,241,7387,117,8625,732,1134,791,4703,909,8503,612,9503,681,6223,612,8343,743,3164,762,5164,685,1954,967,1365,478,638
       Short-term Debt 
0
0
0
2,281,270
0
1,859,762
0
1,611,138
0
1,886,285
0
3,408,406
0
2,385,309
0
2,322,112
0
0
002,322,11202,385,30903,408,40601,886,28501,611,13801,859,76202,281,270000
       Short Long Term Debt 
3,189,448
2,927,445
2,541,706
2,281,270
1,686,888
1,859,763
2,249,184
1,611,137
1,903,631
1,886,285
2,326,380
3,408,406
3,046,829
2,385,309
2,768,482
2,322,112
1,820,788
1,880,741
1,880,7411,820,7882,322,1122,768,4822,385,3093,046,8293,408,4062,326,3801,886,2851,903,6311,611,1372,249,1841,859,7631,686,8882,281,2702,541,7062,927,4453,189,448
       Accounts payable 
381,244
228,661
282,590
232,935
167,598
239,218
320,038
382,628
361,572
385,787
537,885
554,266
433,517
427,433
403,675
420,802
248,007
302,223
302,223248,007420,802403,675427,433433,517554,266537,885385,787361,572382,628320,038239,218167,598232,935282,590228,661381,244
       Other Current Liabilities 
32,758
437,511
679,782
822,532
744,605
473,097
733,461
943,892
967,686
707,330
901,016
846,314
938,438
0
851,742
901,872
930,554
0
0930,554901,872851,7420938,438846,314901,016707,330967,686943,892733,461473,097744,605822,532679,782437,51132,758
   > Long-term Liabilities 
2,369,289
2,803,959
3,377,674
3,948,268
3,398,114
3,724,071
3,870,955
3,621,504
3,533,525
2,793,390
2,644,342
2,098,056
2,755,475
2,830,768
3,016,772
2,780,943
2,624,327
2,228,857
2,228,8572,624,3272,780,9433,016,7722,830,7682,755,4752,098,0562,644,3422,793,3903,533,5253,621,5043,870,9553,724,0713,398,1143,948,2683,377,6742,803,9592,369,289
       Long term Debt Total 
0
0
0
3,519,559
0
3,137,500
0
3,146,798
0
3,048,636
0
1,694,994
0
2,407,429
0
2,365,569
0
0
002,365,56902,407,42901,694,99403,048,63603,146,79803,137,50003,519,559000
       Long term Debt 
1,760,226
2,362,540
2,950,973
3,445,618
2,872,467
3,085,857
3,201,159
3,101,205
3,017,370
2,944,635
2,103,228
1,593,832
2,168,715
2,296,680
2,503,385
2,266,657
2,116,803
1,810,021
1,810,0212,116,8032,266,6572,503,3852,296,6802,168,7151,593,8322,103,2282,944,6353,017,3703,101,2053,201,1593,085,8572,872,4673,445,6182,950,9732,362,5401,760,226
       Capital Lease Obligations Min Short Term Debt
0
0
0
-2,207,115
73,897
-1,808,119
53,025
-1,565,545
44,412
-1,782,284
100,879
-3,307,244
104,240
-2,274,560
101,900
-2,223,200
92,625
90,417
90,41792,625-2,223,200101,900-2,274,560104,240-3,307,244100,879-1,782,28444,412-1,565,54553,025-1,808,11973,897-2,207,115000
       Other Liabilities 
0
441,605
426,701
428,708
451,979
586,571
616,771
474,706
471,744
439,120
440,235
403,062
482,519
0
411,487
415,374
414,899
0
0414,899415,374411,4870482,519403,062440,235439,120471,744474,706616,771586,571451,979428,708426,701441,6050
       Long-term Liabilities Other 
10,162
9,597
9,747
9,739
9,368
8,976
9,040
8,887
8,922
8,771
9,591
9,232
10,107
9,935
9,821
10,322
10,273
9,743
9,74310,27310,3229,8219,93510,1079,2329,5918,7718,9228,8879,0408,9769,3689,7399,7479,59710,162
       Deferred Long Term Liability 
0
132,064
132,589
134,446
133,901
134,605
135,094
145,341
28,953
241,876
41,440
159,081
48,560
0
50,943
247,892
243,934
0
0243,934247,89250,943048,560159,08141,440241,87628,953145,341135,094134,605133,901134,446132,589132,0640
> Total Stockholder Equity
6,834,565
7,347,011
7,659,794
7,752,504
11,250,566
11,569,393
11,719,656
11,624,960
11,706,909
11,557,855
11,641,232
12,034,132
12,361,047
12,310,915
12,375,756
12,397,624
12,406,159
11,913,149
11,913,14912,406,15912,397,62412,375,75612,310,91512,361,04712,034,13211,641,23211,557,85511,706,90911,624,96011,719,65611,569,39311,250,5667,752,5047,659,7947,347,0116,834,565
   Common Stock
0
1,247,202
1,247,202
1,247,202
1,467,296
1,467,296
1,467,296
1,467,296
1,467,296
1,467,296
1,467,296
1,467,296
1,467,296
1,467,296
1,467,296
1,467,296
1,467,296
0
01,467,2961,467,2961,467,2961,467,2961,467,2961,467,2961,467,2961,467,2961,467,2961,467,2961,467,2961,467,2961,467,2961,247,2021,247,2021,247,2020
   Retained Earnings 
2,625,008
3,410,734
3,670,247
3,768,558
3,896,096
4,211,708
4,355,192
4,329,772
4,404,479
4,183,761
4,418,704
4,643,545
4,784,664
3,185,582
4,927,850
4,837,930
4,857,751
3,385,946
3,385,9464,857,7514,837,9304,927,8503,185,5824,784,6644,643,5454,418,7044,183,7614,404,4794,329,7724,355,1924,211,7083,896,0963,768,5583,670,2473,410,7342,625,008
   Capital Surplus 
0
0
0
4,218,797
0
7,528,877
0
7,528,877
0
7,528,877
0
7,528,877
0
7,528,877
0
7,528,877
0
0
007,528,87707,528,87707,528,87707,528,87707,528,87707,528,87704,218,797000
   Treasury Stock000000000000000000
   Other Stockholders Equity 
0
55,116
105,393
94,843
-63,053
-145,094
-137,234
-149,239
5,835,134
-183,356
5,755,232
6,666
6,109,088
223,844
121,469
233,257
226,528
0
0226,528233,257121,469223,8446,109,0886,6665,755,232-183,3565,835,134-149,239-137,234-145,094-63,05394,843105,39355,1160



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue5,445,572
Cost of Revenue-3,645,269
Gross Profit1,800,3031,800,303
 
Operating Income (+$)
Gross Profit1,800,303
Operating Expense-4,805,577
Operating Income639,995-3,005,274
 
Operating Expense (+$)
Research Development182,433
Selling General Administrative975,988
Selling And Marketing Expenses-
Operating Expense4,805,5771,158,421
 
Net Interest Income (+$)
Interest Income-39,521
Interest Expense-223,219
Other Finance Cost-149,433
Net Interest Income-113,308
 
Pretax Income (+$)
Operating Income639,995
Net Interest Income-113,308
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-928,334639,995
EBIT - interestExpense = -223,219
-783,258
-560,039
Interest Expense223,219
Earnings Before Interest and Taxes (EBIT)--705,114
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-928,334
Tax Provision--126,175
Net Income From Continuing Ops-802,159-802,159
Net Income-783,258
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-113,308
 

Technical Analysis of Hepalink
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Hepalink. The general trend of Hepalink is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Hepalink's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Shenzhen Hepalink Pharmaceutical .

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.18 < 3.42 < 3.68.

The bearish price targets are: 2.93 > 2.89 > 2.66.

Tweet this
Shenzhen Hepalink Pharmaceutical  Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Shenzhen Hepalink Pharmaceutical . The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Shenzhen Hepalink Pharmaceutical  Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Shenzhen Hepalink Pharmaceutical . The current macd is 0.04158476.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Hepalink price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Hepalink. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Hepalink price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Shenzhen Hepalink Pharmaceutical  Daily Moving Average Convergence/Divergence (MACD) ChartShenzhen Hepalink Pharmaceutical  Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Shenzhen Hepalink Pharmaceutical . The current adx is 13.85.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Hepalink shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Shenzhen Hepalink Pharmaceutical  Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Shenzhen Hepalink Pharmaceutical . The current sar is 2.7384958.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Shenzhen Hepalink Pharmaceutical  Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Shenzhen Hepalink Pharmaceutical . The current rsi is 66.46. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Shenzhen Hepalink Pharmaceutical  Daily Relative Strength Index (RSI) ChartShenzhen Hepalink Pharmaceutical  Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Shenzhen Hepalink Pharmaceutical . The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Hepalink price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Shenzhen Hepalink Pharmaceutical  Daily Stochastic Oscillator ChartShenzhen Hepalink Pharmaceutical  Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Shenzhen Hepalink Pharmaceutical . The current cci is 268.11.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Shenzhen Hepalink Pharmaceutical  Daily Commodity Channel Index (CCI) ChartShenzhen Hepalink Pharmaceutical  Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Shenzhen Hepalink Pharmaceutical . The current cmo is 46.15.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Shenzhen Hepalink Pharmaceutical  Daily Chande Momentum Oscillator (CMO) ChartShenzhen Hepalink Pharmaceutical  Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Shenzhen Hepalink Pharmaceutical . The current willr is -10.63829787.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Shenzhen Hepalink Pharmaceutical  Daily Williams %R ChartShenzhen Hepalink Pharmaceutical  Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Shenzhen Hepalink Pharmaceutical .

Shenzhen Hepalink Pharmaceutical  Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Shenzhen Hepalink Pharmaceutical . The current atr is 0.095922.

Shenzhen Hepalink Pharmaceutical  Daily Average True Range (ATR) ChartShenzhen Hepalink Pharmaceutical  Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Shenzhen Hepalink Pharmaceutical . The current obv is 18,991,872.

Shenzhen Hepalink Pharmaceutical  Daily On-Balance Volume (OBV) ChartShenzhen Hepalink Pharmaceutical  Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Shenzhen Hepalink Pharmaceutical . The current mfi is 67.74.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Shenzhen Hepalink Pharmaceutical  Daily Money Flow Index (MFI) ChartShenzhen Hepalink Pharmaceutical  Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Shenzhen Hepalink Pharmaceutical .

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-27ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-28RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-17ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-31ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-05ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-06WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-18WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.

6.3. Candlestick Patterns

Shenzhen Hepalink Pharmaceutical  Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Shenzhen Hepalink Pharmaceutical  based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5066.464
Ma 20Greater thanMa 502.825
Ma 50Greater thanMa 1002.810
Ma 100Greater thanMa 2003.031
OpenGreater thanClose3.010
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Hepalink with someone you think should read this too:
  • Are you bullish or bearish on Hepalink? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Hepalink? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Shenzhen Hepalink Pharmaceutical 

I send you an email if I find something interesting about Shenzhen Hepalink Pharmaceutical .


Comments

How you think about this?

Leave a comment

Stay informed about Shenzhen Hepalink Pharmaceutical .

Receive notifications about Shenzhen Hepalink Pharmaceutical  in your mailbox!